Fortis Healthcare Limited (FORTIS)

Healthcare · Healthcare Services · NSE · Updated 15 July 2026

₹976.15 ↑ 22.13% (1Y)

🎯 Key Takeaways

Fortis Healthcare is transitioning from a period of regulatory and operational headwinds to a structured recovery phase driven by capacity expansion, margin improvement, and domestic growth initiatives. Management is targeting 15%+ hospital revenue growth in FY27 and a 25% EBITDA margin by FY28, supported by 500+ bed additions and operational efficiency gains.
Revenue declined 3% QoQ to ₹1,928 in Q3FY25.
⚠️ Regulatory scrutiny from EOW, SEBI, and ED related to past fund diversions and related-party transactions, though assessed as low and non-material, re

Market Cap

₹72,752

P/E Ratio

94.6

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About FORTIS 📊 Interactive Charts

📖 The Story

Fortis Healthcare is transitioning from a period of regulatory and operational headwinds to a structured recovery phase driven by capacity expansion, margin improvement, and domestic growth initiatives. Management is targeting 15%+ hospital revenue growth in FY27 and a 25% EBITDA margin by FY28, supported by 500+ bed additions and operational efficiency gains. The company is no longer in distress but has not yet entered a mature cash cow phase, instead positioning itself as a turnaround story with scalable infrastructure and improving profitability.

📰 What's Happening

In the latest filing on 2026-06-24, Fortis announced a 48-hour trading window closure following the release of un-audited Q1FY27 results, signaling the end of the fiscal year and preparation for audited results. The prior filing on 2026-05-29 revealed FY26 consolidated revenue of ₹9,128 crores, up 17.3% YoY, with PAT surging 31.5% to ₹1,064 crores and EBITDA margin expanding to 22.8%. The company added 800 new beds and achieved 13 facilities exceeding 20% EBITDA margin. Board approval on 2026-05-22 confirmed a ₹1 per share final dividend and audited FY26 results showing ₹106,419 lakhs net profit — a 69.9% YoY increase. The May 22 board meeting also approved cost auditors and CSR policy, reinforcing governance focus. Management highlighted 500+ bed expansion by FY27 and INR900 crore annual capex (40% growth capex) as key drivers of future momentum.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	1,643	1,657	1,770	1,680	1,786	1,859	1,988	1,928
Operating Profit	295	282	347	298	394	356	388	420
OPM %	16.5%	16.4%	18.6%	16.9%	21.3%	18.4%	21.9%	19.4%
Net Profit	138	124	184	134	203	174	193	254
EPS	₹1.76	₹1.48	₹2.30	₹1.78	₹2.37	₹2.20	₹2.34	₹3.28

Operating performance shows consistent upward momentum in revenue and profitability, with Q3FY25 revenue of ₹1,928 crores and OPM of 19.4% reflecting stabilization after earlier volatility. The trajectory indicates accelerating growth from ₹1,643 crores in Q4FY23 to ₹1,928 crores in Q3FY25, accompanied by margin expansion and rising PAT. This trend aligns with management’s disclosed focus on capacity utilization and diagnostic revenue growth, which grew 8.5% YoY in FY26. The company is transitioning from flat occupancy to ramp-up phase in new facilities, supporting revenue visibility and margin sustainability.

🔮 Management Outlook & What's Next

Management has provided clear forward guidance, targeting 15%+ hospital revenue growth in FY27 and 150 bps EBITDA margin improvement in the current financial year, with a long-term goal of 25% EBITDA margin by FY28. They expect international oncology pricing pressures to normalize while domestic expansion — including 500+ bed additions and 800 new beds already added — drives occupancy and revenue growth without lag. Digital health initiatives are being advanced internally, and capex of INR900 crores annually (60% maintenance, 40% growth) is being deployed to fuel scalable infrastructure. Management remains confident in sustaining double-digit diagnostic growth and improving occupancy trends.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Healthcare Services

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Apollo Hospitals Enterprise Limited	1.16 L Cr	64.5	20.5%	21.9%	0.64
Max Healthcare Institute Limited	1.02 L Cr	101.2	—	—	—
Fortis Healthcare Limited	72,752	94.6	—	—	—
Aster DM Healthcare Limited	39,048	7.1	—	—	—
Narayana Hrudayalaya Ltd.	37,625	47.7	—	—	—
Global Health Limited	33,405	65.8	—	—	—
Krishna Institute of Medical Sciences Limited	30,477	80.3	—	—	—
Dr. Lal Path Labs Ltd.	26,871	63.6	—	—	—
Syngene International Limited	18,295	36.3	—	—	—
Dr. Agarwal's Health Care Limited	14,266	88.8	14.9%	6.8%	0.13

🔗 Peer Stock Analyses

APOLLOHOSP MAXHEALTH ASTERDM NH MEDANTA

⚠️ Risk Factors

1. Regulatory scrutiny from EOW, SEBI, and ED related to past fund diversions and related-party transactions, though assessed as low and non-material, remains a monitoring risk. 2. International oncology business continues to face pricing pressure and reduced patient volumes, which could impact near-term international revenue visibility. 3. Execution risk in scaling new bed capacity and achieving targeted occupancy levels without margin dilution. 4. High valuation (P/E of 94.6) reflects elevated investor expectations, making the stock sensitive to any slowdown in growth or margin delivery.

📋 Recent Filings

🧠 Analyst's Read

Fortis Healthcare is executing a clear turnaround narrative with measurable progress in revenue growth, margin expansion, and capex-driven capacity buildout, supported by strong profitability and shareholder returns. The key watchpoint is execution discipline in new facility ramp-up and sustained margin improvement, particularly as it targets 25% EBITDA margin by FY28. Investors should monitor quarterly occupancy trends and international business recovery, as these will determine the pace of sustainable growth beyond current guidance.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on FORTIS

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-15.

📡 Get AI alerts when FORTIS files new disclosures

Track FORTIS filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track FORTIS — Free

Free account · 2 AI queries/day